Decreasing Hemoglobin A1c: Progress or Pathology?
Abstract
A 67-year-old woman with multiple comorbidities presented to the clinic for a routine follow-up of her chronic conditions, including diabetes management. She had been followed by multiple residents over the years and was noted to have a declining hemoglobin A1c (HgbA1c) despite discontinuation of diabetes medications and no significant lifestyle changes. The patient reported episodes of hypoglycemia, dizziness, and multiple falls, resulting in several emergency department visits. Her HgbA1c had decreased from a prior high of 10% to 5.4%. Further evaluation included laboratory tests, imaging, and an e-consult to Endocrinology. Diagnostic evaluation revealed elevated insulin (47.8 μU/mL; reference range: 2-25 μU/mL) and c-peptide (11.2 ng/mL; reference range: 0.5-2 ng/mL) in the presence of hypoglycemia (serum glucose 42 mg/dL). Computed tomography (CT) and magnetic resonance imaging (MRI) identified a mass in the pancreatic tail. Endocrinology recommended urgent surgical consultation, and one month later, the patient underwent distal pancreatectomy and splenectomy. Final pathology confirmed an insulinoma. She was subsequently followed by her primary care physician, surgical team, and Endocrinology, resumed metformin, and has had no further hypoglycemic episodes or falls. Insulinoma is a rare diagnosis that, if overlooked, can lead to significant morbidity. While treatment is typically straightforward once identified, diagnosis often requires careful attention to subtle…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.